Abstract Details

Title Glioblastoma Clinical Trials for Urban and Rural Patients in the United States from 2010-2020

Topic Neuro-oncology

Presentation(s) Neuro-oncology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 003

Objective

To describe clinical trial opportunities for patients with glioblastoma in rural and urban United States(US).

Background Median survival of glioblastoma is 20.9 months. Clinical trials are vital to discover better treatments. Prior study suggested that glioblastoma patients who participate in clinical trials may live longer. Not all have the opportunity to enroll in a trial due lack of trial opportunities in their area of residence.

Design/Methods We queried ClinicalTrials.gov for glioblastoma interventional treatment trials opened between 2010-2020 in the US. We created a SQL data base of sites and trials and leveraged Google API Places to find name and street addresses for sites, and Google’s Geocode API to determine the county for each site. USDA Rural-Urban Continuum Codes(RUCC) were applied to each county. RUCC 1-3 were classified as urban and RUCC 4-9 rural. We used z-ratios to compare differences in trial types between urban and rural locations. We also queried the United Council for Neurological Subspecialties(UCNS) registry to determine location of certified neuro-oncologists.

Results 406 trials were conducted at 1491 sites with unique addresses, yielding 3972 trial locations. 8.7% of unique sites were rural, but offered only 5.5% of trials. Rural sites opened an average of 1.7 trials and urban sites 2.8. Rural sites offered significantly more phase II trials (63% vs 57%, p = 0.03) and significantly fewer phase I trials (22% vs 28%, p= 0.01). Rural locations were significantly more likely to offer federally-sponsored trials (p<0.002). No investigator-initiated studies were offered at rural locations. There are 275 UCNS certified neuro-oncologists in the US; all are urbanly located.

Conclusions

The National Comprehensive Cancer Network guidelines top recommendation for management of newly diagnosed glioblastoma is consideration of a clinical trial. From 2010-2020 a minority of trials have been opened in rural areas, suggesting that rurally located patients may have more difficulty accessing clinical trials.

Authors/Disclosures
Kathryn S. Nevel, MD (Indiana University School of Medicine) PRESENTER	Dr. Nevel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Servier Pharmaceuticals. Dr. Nevel has received publishing royalties from a publication relating to health care. Dr. Nevel has received personal compensation in the range of $500-$4,999 for serving as a Interviewer with Continuum Audio.
Samuel D. Capouch, MD	Dr. Capouch has nothing to disclose.
Lisa M. Arnold, DO (Intermountain Medical Center)	Dr. Arnold has nothing to disclose.
Nimish A. Mohile, MD, FAAN	The institution of Dr. Mohile has received research support from Novocure.
Katherine B. Peters, MD, PhD, FAAN (Duke University Medical Center)	Dr. Peters has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sapience. Dr. Peters has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NuVox Therapeutics. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ONO Pharmaceutical. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Telix. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AnHeart. Dr. Peters has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Rigel. The institution of Dr. Peters has received research support from Biomimetix. The institution of Dr. Peters has received research support from Servier. The institution of Dr. Peters has received research support from Varian. The institution of Dr. Peters has received research support from Sapience. The institution of Dr. Peters has received research support from Ono Pharmaceuticals.
Alissa A. Thomas, MD, FAAN (University of Vermont Medical Center)	The institution of Dr. Thomas has received research support from Novocure. The institution of Dr. Thomas has received research support from Ono Pharmaceuticals.

��ɫ��

��ɫ��